This course will expand on both classical and cutting edge pharmacological strategies proposed to mitigate the consequences of altered signal transduction in cancer. Students will have the opportunity to develop knowledge on these molecular events and how they can be targeted to improve clinical outcomes. Students will integrate lecture material with assigned readings and assignments.
BCH210H1/ BCH242Y1/ [ CHM361H5(UTM) and CHM362H5(UTM)], [ BIOC12H3(UTSC) and BIOC13H3(UTSC)], CHMB62H3(UTSC), and completion of at least 9.0 credits. Students who do not meet the prerequisite are encouraged to contact the Department.
